Alberto Espay has published extensively on Parkinson's disease and leads the first phenotype-agnostic biomarker development program for patients with neurodegenerative diseases (CCBP) designed to deploy bioassays aiming at matching available therapies with those most likely to benefit, regardless of clinical diagnosis.
~~tag-text~~
An estimated 80 million people live with a neurodegenerative disease, with this number expected to double by 2050. Despite decades of research and billions in funding, there are no medications that can slow, much less stop, the progress of these diseases.... SEE MORE